Neuraxpharm is pleased to announce the publication of its ESG Report for 2023, highlighting the continued efforts made by the Company to improve its sustainability performance.
In this report, Neuraxpharm details its efforts towards reducing its environmental impact, promoting ethical business practices, and contributing positively to its communities and the world around it.
Neuraxpharm is committed to supporting the CNS community, its employees, and safeguarding its patients as the Company continues to provide differentiated CNS products and solutions to address unmet patient needs.
Read the report to discover Neuraxpharm’s performance metrics in ESG-related topics, including its carbon footprint calculation and increasing alignment with the EU Corporate Sustainability Reporting Directive (CSRD).
